Rectum Cancer Clinical Trial
Official title:
Evaluation of Pelvic Peritonization in Robotic or Laparoscopic Low Anterior Resection for Rectal Cancer
A randomized controlled clinical trial to compare the short and long outcomes of low anterior resection for middle-low rectal cancer with or without pelvic peritonization.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | September 1, 2024 |
Est. primary completion date | August 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Matching the diagnostic criteria of rectal adenocarcinoma - Laparoscopic or robotic radical surgery for rectal cancer - Preoperative TNM staging T1-3N0-2M0 - No history of malignant tumors by preoperative examination - Middle and low rectal cancer - Tumor size of 4 cm or less - ASA 1-3 scores - Written informed consent by the patient - The patient is willing to randomize to any group Exclusion Criteria: - Previous abdominal surgery - Past malignant tumor history - Preoperative examination suggests distant metastasis - Be participating or have participated in other clinical studies related to rectal cancer surgery within 6 months - Emergency operation Elimination criteria - The tumor is confirmed to be T4b during the operation or other tumors are found to be combined with other tumors during the operation - The anastomosis is located above the peritoneum reflex - Intraoperative conversion to laparotomy - Change the surgical method to perform Miles or Hartmann surgery - Postoperative pathologically confirmed non-adenocarcinoma - The patient asked to withdraw |
Country | Name | City | State |
---|---|---|---|
China | General Surgery Center of PLA | Chongqing |
Lead Sponsor | Collaborator |
---|---|
Southwest Hospital, China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Grade III-IV complications | The rate of grade III-IV complication according to Clavien-Dindo classification after low anterior resection | 30 days | |
Secondary | Rate of reoperation | The rate of reoperation after leakage | 30 days | |
Secondary | Detection of inflammation markers | C-reactive protein(1, 3, 5, 7 days after operation, and 1 day before discharge, all blood drawn is venous blood) | 7 days | |
Secondary | The rate of anastomotic leakage | Clinical diagnostic criteria for anastomotic leakage: 1. Abdominal and systemic infection symptoms: abdominal pain, bloating, fever, elevated white blood cells, PCT, CRP and other inflammation indicators; 2. Gas, pus, feces passing through the pelvic drainage tube, abdominal incision, etc. | 30 days | |
Secondary | Hospital time | Comparison of hospital stay between the two groups | 30 days | |
Secondary | Overall complication rate | Overall complication rate include I-IV grade | 30days | |
Secondary | Estimated blood loss | Blood loss will be measured according to the suction and the weight of wet gauze, and then minus the irrigation | 1 day | |
Secondary | Operation time | The time from start to end of surgery | 1 day | |
Secondary | Postoperative bleeding | Postoperative intra-abdominal bleeding | 7 days | |
Secondary | Intestinal obstruction | Incidence of intestinal obstruction caused by various reasons after surgery | 30 days | |
Secondary | Readmission rate | Rate of hospital readmissions due to complications after discharge | 30 days | |
Secondary | LARS | Low Anterior resection syndrome caused by rectal surgery | 12 months | |
Secondary | Acute inflammatory Response | Procalcitonin(1, 3, 5, 7 days after operation, and 1 day before discharge, all blood drawn is venous blood) | 7 days | |
Secondary | Acute inflammatory Response | Check Neutrophils(1, 3, 5, 7 days after operation, and 1 day before discharge, all blood drawn is venous blood) | 7 days | |
Secondary | Detection of other inflammation markers | interleukin-6(1, 3, 5, 7 days after operation, and 1 day before discharge, all blood drawn is venous blood) | 7 days | |
Secondary | Treatment cost | Comparison of cost between the two groups | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT00409994 -
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04371198 -
Patient-Derived Organoids for Rectal Cancer
|
N/A | |
Recruiting |
NCT04916990 -
Improving Care for Rural Patients With Solid Tumors
|
N/A | |
Active, not recruiting |
NCT05305820 -
Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy
|
N/A | |
Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
Completed |
NCT03843957 -
Effectiveness and Implementation of mPATH-CRC
|
N/A | |
Completed |
NCT02423226 -
Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer
|
Phase 2 | |
Completed |
NCT00509444 -
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
|
Phase 3 | |
Completed |
NCT00379743 -
Partnership for Healthy Seniors
|
N/A | |
Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
Not yet recruiting |
NCT06066931 -
Reconstruction of the Pelvic Floor and Perineal Wound After Rectal ELAPE
|
N/A | |
Recruiting |
NCT02738359 -
Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening
|
||
Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
Active, not recruiting |
NCT02458664 -
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer
|
N/A | |
Withdrawn |
NCT03257332 -
Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
|
||
Recruiting |
NCT05715255 -
Adaptive Symptom Self-Management Immunotherapy Study
|
N/A | |
Completed |
NCT02641691 -
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
|
Phase 2 | |
Recruiting |
NCT04405206 -
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer
|
||
Recruiting |
NCT03573791 -
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
|